Search the database for deliberate release of GM medicinal products
Displaying 1 - 1 of 1
EU record number | Title | Company / Sponsor | Treated organism | Genetic modification |
---|---|---|---|---|
Only notified under the "contained use" procedure. Dossier submitted on 25/04/2018. | A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7) | Kite Pharma | Humans | Chimeric antigen receptor against CD19 |